News

Category: Advancements in Alzheimer’s disease

Focused ultrasound technique leads to release of neurodegenerative disorders biomarkers

The Source, Washington University in St. Louis - Feb 3, 2023

FDA APPROVES LEQEMBI™ (LECANEMAB-IRMB) UNDER THE ACCELERATED APPROVAL PATHWAY FOR THE TREATMENT OF ALZHEIMER’S DISEASE

Eisai Co., Ltd. - Jan 06 2023

WashU, Eisai form drug discovery collaboration

The Source, Washington University in St. Louis - Dec 14, 2022

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease

Roche - Nov 14, 2022

LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE

Eisai Co., Ltd. - Sept 27 2022

Roche provides update on Alzheimer’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease

F. Hoffmann-La Roche Ltd - June 16, 2022

Blood test for Alzheimer’s highly accurate in large, international study

The Source, Washington University in St. Louis - Feb 22, 2022

Dementia First blood test to help diagnose Alzheimer’s goes on sale

AP News - November 30, 2020

Why Didn’t She Get Alzheimer’s? The Answer Could Hold a Key to Fighting the Disease

New York Times - Nov 4 2019

‘Reports of My Death Are Greatly Exaggerated.’ Signed, Aducanumab

Alzforum - Oct 24 2019